FIELD: chemistry.
SUBSTANCE: present invention relates to immunology. Proposed is a bispecific antibody that binds CD47 and CD19.
EFFECT: this antibody inhibits the interaction between CD47 and SIRPα and may find further application in the treatment of various pathologies associated with abnormal expression and / or activity of CD47 and CD19, including tumors.
12 cl, 14 dwg, 4 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTI-SIRPα ANTIBODIES | 2019 |
|
RU2812199C2 |
| BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | 2019 |
|
RU2798246C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| ALDEHYDE MARKED IMMUNOGLOBULIN POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2606016C2 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| OBTAINING MULTISPECIFIC MIXTURES OF ANTIBODIES AND METHODS OF USE THEREOF | 2018 |
|
RU2815826C2 |
| METHODS FOR GENERATION OF MULTISPECIFIC AND MULTIVALENT ANTIBODIES | 2011 |
|
RU2608640C2 |
| ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | 2021 |
|
RU2815823C2 |
| ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
